← Back to Clinical Trials
Recruiting NCT06638892

NCT06638892 Using PrEP, Doing It for Ourselves

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06638892
Status Recruiting
Phase
Sponsor Duke University
Condition HIV Prevention
Study Type INTERVENTIONAL
Enrollment 1,000 participants
Start Date 2026-02-13
Primary Completion 2029-06

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Using PrEP, Doing it for Ourselves (UPDOs)Standard of Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,000 participants in total. It began in 2026-02-13 with a primary completion date of 2029-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to test a new online program called UPDOs Protective Styles to help people in the southeastern United States learn about and start using PrEP (pre-exposure prophylaxis), a medicine that helps prevent HIV. The study focuses on people who may be at higher risk for HIV and have not had equal access to PrEP. The main questions it aims to answer are: Does UPDOs help more people trust and understand PrEP? Does UPDOs increase the number of people who start and continue using PrEP? Researchers will compare two groups: One group will use UPDOs, which includes six weekly videos, blog discussions, and access to telehealth services through Q Care Plus. The other group will receive standard HIV prevention materials from the CDC. Participants will: Be recruited from 32 beauty salons in areas with high HIV rates. Complete surveys at the start of the study and again at 6, 12, 24, 32, and 52 weeks. Have access to HIV testing and PrEP prescriptions through Q Care Plus. This study will also look at how well the program works in different communities and how easy it is to use and share.

Eligibility Criteria

Inclusion Criteria: * Black * cisgender female * Ages 18+ Exclusion Criteria: * Under 18 years of age * Does not identify as Black * Not a cisgender female

Contact & Investigator

Central Contact

Niasha Fray, MA, MSPH

✉ Niasha.Fray@Duke.edu

📞 919-668-8325

Principal Investigator

Schenita Randolph, PhD

PRINCIPAL INVESTIGATOR

Duke University

Frequently Asked Questions

Who can join the NCT06638892 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying HIV Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06638892 currently recruiting?

Yes, NCT06638892 is actively recruiting participants. Contact the research team at Niasha.Fray@Duke.edu for enrollment information.

Where is the NCT06638892 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT06638892 clinical trial?

NCT06638892 is sponsored by Duke University. The principal investigator is Schenita Randolph, PhD at Duke University. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology